Just five months after the Zika virus was declared a global public health emergency, a scientific team’s feverish efforts to create a vaccine against the viral threat have borne promising fruit: With a single shot of two different types of vaccine, experimental mice gained near-total immunity to Zika for at least two months.
Just five months after the Zika virus was declared a global public health emergency, a scientific team’s feverish efforts to create a vaccine against the viral threat have borne promising fruit: With a single shot of two different types of vaccine, experimental mice gained near-total immunity to Zika for at least two months.
Writing in the journal Nature on Tuesday, a U.S.-Brazilian team of scientists reported that two distinct vaccine candidates conferred powerful protection from Zika infection when they were delivered by intra-muscular injection to mice.
“We were very surprised — and quite impressed — that a single shot of either of these vaccines provided complete protection,” said study co-author Dr. Dan H. Barouch, who after years of work on vaccines against the HIV virus pivoted in late January to work on Zika.
“Of course, we need to be cautious about extrapolating” from a study that has so far only shown success in mice, said Barouch, who directs vaccine research at Beth Israel Deaconess Medical Center in Boston.
But several of the study’s findings “certainly raise optimism that the development of a safe and effective vaccine against Zika virus for humans may be successful,” he added.
The Zika vaccine effort is a race against time. Since its arrival in Brazil in 2013, the Zika virus has marched steadily north. Carried by the Aedes aegypti mosquito, the virus is already spreading vigorously in Puerto Rico and is expected to circulate inside the continental United States this summer.
The Centers for Disease Control and Prevention has concluded that Zika infection in pregnant women is the cause of grievous brain abnormalities in the infants they bear. For those who are not pregnant, Zika infection is generally not dangerous. But it can, in rare cases, cause Guillain-Barre syndrome, a life-threatening condition in which the immune system attacks the peripheral nervous system, causing partial paralysis that is generally temporary.
The Boston-based team also discerned how the tested vaccines worked to provide protection — an important milestone in building a vaccine. Soon after their first shot of either vaccine, the immune systems of lab mice quickly mounted an army of circulating antibodies that recognized and attacked Zika virus as soon as it began replicating.
Such “antibody protection,” produced by the immune system’s B-cells, is not generally as enduring as the long-term immune memory produced by T-cells. But “it’s good: it makes a vaccine that’s nice and neat and simple,” said Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases.
Fauci called the vaccine candidates’ early success “an important step on the road to getting vaccines into humans.” He confirmed that several other Zika vaccine candidates are being tested in animals, and that very early testing in humans could begin as early as late August.
The two vaccine candidates described in Nature represent two very different approaches to training the immune system’s killing power on the Zika virus. One takes the whole of a single Zika virus, inactivates it by removing the machinery that makes it replicate, and shows it to the immune system. The other candidate shows the immune system only the distinctive outer sheath of the Zika virus in a bid to prompt attacks on anything enclosed in such an envelope.
Both approaches worked in several different strains of laboratory mice. But while “inactivated virus” vaccines are already in wide use, so-called “DNA vaccines,” which show the immune system small pieces of a virus, have never been approved for use in humans in the United States.
“Some call them vaccines of the future,” said Barouch of the DNA vaccines. Whether they lend themselves to large-scale production and distribution remains unclear, he said. “But they do have a variety of … technological advantages compared to the traditional approaches” — not least that vaccine designers can make rapid changes in the mix of puzzle pieces shown to the immune system.
Given the uncertainties of developing vaccines for emergency use, “a diversity of approaches is always beneficial,” he added.
In the experiments, the mice cleared Zika virus from their bloodstreams even when their army of antibodies was “relatively modest,” said Barouch. With an additional booster shot or two, he said the experimental vaccines could prompt an immune response a hundred times as strong, if needed.